Close Menu

NEW YORK (GenomeWeb) – Sera Prognostics plans this year to launch its PreTRM proteomic test for assessing pregnant women's risk of preterm delivery, company Chairman and CEO Gregory Critchfield told GenomeWeb this week.

The firm is currently in the process of validating the test in a 5,500-patient cohort collected through its Proteomic Assessment of Preterm Risk clinical study and expects results of the study to be available in the second quarter of 2015 with commercial launch of the test following around mid-year, Critchfield said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.